BRAF V600E mutation and papillary thyroid cancer
- PMID: 23925627
- PMCID: PMC3779839
- DOI: 10.1001/jama.2013.8592
BRAF V600E mutation and papillary thyroid cancer
Comment in
-
BRAF V600E mutation and papillary thyroid cancer--in reply.JAMA. 2013 Aug 7;310(5):535-6. doi: 10.1001/jama.2013.8595. JAMA. 2013. PMID: 23925628 No abstract available.
Comment on
-
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190. JAMA. 2013. PMID: 23571588 Free PMC article.
-
Molecular testing in thyroid cancer: BRAF mutation status and mortality.JAMA. 2013 Apr 10;309(14):1529-30. doi: 10.1001/jama.2013.3620. JAMA. 2013. PMID: 23571594 No abstract available.
References
-
- Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA. 2013;309(14):1529–1530. - PubMed
-
- Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390–4398. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials